Lexeo Therapeutics Inc
LXEO
Company Profile
Business description
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Contact
345 Park Avenue South
Floor 6
New YorkNY10010
USAT: +1 212 547-9879
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
All roads lead back home for Guzman Y Gomez.
stocks
Chart of the Week: The long term headwinds facing copper shares
The key factors challenging the bull case for copper demand.
stocks
Australia’s oldest REIT undervalued
This REIT remains undervalued as trophy properties shine through.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,930.90 | 9.20 | 0.10% |
| CAC 40 | 8,491.99 | 154.70 | 1.86% |
| DAX 40 | 25,599.03 | 558.75 | 2.23% |
| Dow JONES (US) | 52,745.29 | 440.05 | 0.84% |
| FTSE 100 | 10,690.18 | 211.84 | 2.02% |
| HKSE | 23,055.03 | 174.01 | 0.76% |
| NASDAQ | 25,911.80 | 128.23 | -0.49% |
| Nikkei 225 | 68,733.15 | 1,741.81 | -2.47% |
| NZX 50 Index | 13,582.19 | 28.31 | -0.21% |
| S&P 500 | 7,489.11 | 5.88 | 0.08% |
| S&P/ASX 200 | 8,724.50 | 13.90 | 0.16% |
| SSE Composite Index | 4,028.90 | 83.54 | -2.03% |